EUVIMEDEUVIMED entdecken
Crossref

A new perspective on therapies involving B-cell depletion in autoimmune diseases

Sulieman Ibraheem Shelash Al-Hawary, Saade Abdalkareem Jasim, Ahmed Hjazi, Himayat Ullah, Pooja Bansal, Mahamedha Deorari, I B Sapaev, Ahmed Ali Ami, Karrar Hatif Mohmmed, Munther Kadhim Abosaoda

Molecular Biology Reports · 2024

DOI: 10.1007/s11033-024-09575-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Biology Reports, 2024. Verfasst von Sulieman Ibraheem Shelash Al-Hawary und 9 weiteren Autor:innen. Beteiligte Einrichtung: Al Al-Bayt University, Al-Mafraq, Jordan. Hauptthemen laut MEDLINE: Autoimmune Diseases, B-Lymphocytes, Lymphocyte Depletion. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 101 Literaturangaben. Gefördert von: Shaqra University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

It has been rediscovered in the last fifteen years that B-cells play an active role in autoimmune etiology rather than just being spectators. The clinical success of B-cell depletion therapies (BCDTs) has contributed to this. BCDTs, including those that target CD20, CD19, and BAFF, were first developed to eradicate malignant B-cells. These days, they treat autoimmune conditions like multiple sclerosis and systemic lupus erythematosus. Particular surprises have resulted from the use of BCDTs in autoimmune diseases. For example, even in cases where BCDT is used to treat the condition, its effects on antibody-secreting plasma cells and antibody levels are restricted, even though these cells are regarded to play a detrimental pathogenic role in autoimmune diseases. In this Review, we provide an update on our knowledge of the biology of B-cells, examine the outcomes of clinical studies employing BCDT for autoimmune reasons, talk about potential explanations for the drug's mode of action, and make predictions about future approaches to targeting B-cells other than depletion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Autoimmune DiseasesB-LymphocytesLymphocyte DepletionAnimalsHumansAntigens, CD19Antigens, CD20B-Cell Activating FactorLupus Erythematosus, SystemicMultiple Sclerosis

Stichwörter der Autor:innen

Autoimmune diseasesB-cellB-cell depletion therapiesBCDT

Substanzen

Antigens, CD19Antigens, CD20B-Cell Activating Factor

Autor:innen und Institutionen

  • Al Al-Bayt University, Al-Mafraq, Jordan.
  • Medical Laboratory Techniques Department, Al-Maarif University College, Anbar, Iraq.
  • Department of Medical Laboratory, College of Applied Medical Sciences, Prince Sattam Bin Abdulaziz University, 11942, Al-Kharj, Saudi Arabia.
  • College of Medicine, Shaqra University, 15526, Shaqra, Saudi Arabia. Himayatullah@su.edu.sa.
  • Department of Biotechnology and Genetics, Jain (Deemed-to-Be) University, Bengaluru, Karnataka, 560069, India.
  • Department of Allied Healthcare and Sciences, Vivekananda Global University, Jaipur, Rajasthan, 303012, India.

Förderung

  • Shaqra University

Zitieren

APA

Al-Hawary, S. I. S., Jasim, S. A., Hjazi, A., Ullah, H., Bansal, P., Deorari, M., Sapaev, I. B., Ami, A. A., Mohmmed, K. H., & Abosaoda, M. K. (2024). A new perspective on therapies involving B-cell depletion in autoimmune diseases. Molecular Biology Reports. https://doi.org/10.1007/s11033-024-09575-6

Vancouver

Al-Hawary SIS, Jasim SA, Hjazi A, Ullah H, Bansal P, Deorari M, et al. A new perspective on therapies involving B-cell depletion in autoimmune diseases. Molecular Biology Reports. 2024. doi:10.1007/s11033-024-09575-6

BibTeX
@article{AlHawary2024,
  author = {Al-Hawary, Sulieman Ibraheem Shelash and Jasim, Saade Abdalkareem and Hjazi, Ahmed and Ullah, Himayat and Bansal, Pooja and Deorari, Mahamedha and Sapaev, I B and Ami, Ahmed Ali and Mohmmed, Karrar Hatif and Abosaoda, Munther Kadhim},
  title = {A new perspective on therapies involving B-cell depletion in autoimmune diseases},
  journal = {Molecular Biology Reports},
  year = {2024},
  doi = {10.1007/s11033-024-09575-6}
}
Kostenlos starten →